TNFSF10 and renal carcinoma: As shown in Figure 7a, combined treatment with IITZ-01 and TRAIL augmented sub-G1 population and PARP cleavage in other renal cancer cells (A498), human lung cancer cells (A549) and breast cancer cells (MCF7).